TA Associates is exploring a sale of Healix Infusion Care, three sources tell Axios Pro. It’s the third infusion platform known to be on the block, reflecting its reputation as a lucrative health care services sector. Healix is generating about $20 million in EBITDA, the first and second sources say.
Read the full article: TA Associates-Backed Healix Infusion Care on the Block //
Source: https://www.axios.com/pro/health-tech-deals/2025/06/12/ta-associates-healix-infusion-care-sale